Physician profile
Robert Rotenberg
NPI 1144685207
$3,489.76
in general payments reported to CMS, 2019-2025
24 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $402 · 2024: $1,611 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $734.23 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $507.25 | 2023-2025 | |
| Abbvie INC. | $456.59 | 2023-2025 | |
| Lilly USA, LLC | $342.98 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $279.57 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $218.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $216.96 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $154.75 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $64.98 | 2024-2025 | Veozah |
| Amgen INC. | $62.68 | 2024-2025 | Krystexxa |
| Medtronic, INC. | $62.00 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Watermark Medical, INC. | $44.99 | 2024 | |
| Merck Sharp & Dohme LLC | $44.84 | 2025 | Capvaxive, Lagevrio |
| Sumitomo Pharma America, INC. | $43.28 | 2024-2025 | Gemtesa |
| Novavax INC | $38.62 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $34.73 | 2025 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.55 | 2024 | Ofev |
| Axsome Therapeutics, INC. | $30.34 | 2024 | Sunosi |
| Dexcom, INC. | $26.44 | 2025 | Dexcom G6 Transmitter |
| Fidia Pharma USA INC. | $24.47 | 2025 | Hymovis |
| Horizon Therapeutics Plc | $22.99 | 2023 | Krystexxa |
| Cequr Corporation | $16.00 | 2025 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.64 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $14.94 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rotenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.